Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.49 |
| ▸ | CTSS | P25774 | 11/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1235160 | 1.00 | CTSK (0.49) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL4279525 | 1.00 | CTSK (0.49) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL1277727 | 0.91 | ITGB3 (0.50) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL2860662 | 0.91 | ITGB3 (0.50) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL13640176 | 0.91 | ITGB3 (0.50) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL9301989 | 0.91 | CTSK (0.48) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL5702493 | 0.91 | CTSK (0.48) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL30385524 | 0.90 | CYP1A2 (0.47) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL30589487 | 0.90 | ITGB3 (0.49) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL14629603 | 0.88 | CTSK (0.46) | CTSKCTSSCTSLCTSBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112062755-B | Near-infrared fluorescent molecular probe for detecting aspartyl aminopeptidase, preparation method and application | 中国药科大学 | 2022-04-12 | — | — | CN | claimed |
| CN-112062755-A | Near-infrared fluorescent molecular probe for detecting aspartyl aminopeptidase, preparation method and application | 中国药科大学 | 2020-12-11 | — | — | CN | claimed |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| US-20260008750-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING PRODUCTION OF TRIMETHYLAMINE | CLEVELAND CLINIC FOUND (US) | 2026-01-08 | — | — | US | disclosed |
| EP-3604326-B1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORP (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250241926-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-31 | — | — | US | disclosed |
| EP-4419207-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025092841-A1 | PSMA COMPOUND, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF | 山东威智知科药业有限公司 | 2025-05-08 | — | — | WO | disclosed |
| CN-100390169-C | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2008-05-28 | — | — | CN | disclosed |
| CN-1753888-A | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2006-03-29 | — | — | CN | disclosed |
| US-20040249187-A1 | Method for producing chiral amino acid derivatives | BAYER CHEMICALS AG (DE) | 2004-12-09 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
| EP-0757677-B1 | BENZOCYCLOHEXYLIMIDAZOLETHIONE DERIVATIVES | SYNTEX LLC (US) | 2003-06-18 | — | — | EP | disclosed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0757677-A1 | BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| WO-1995029165-A2 | BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | CTSK 2636/4885CTSS 2861/4885CTSL 2454/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | CTSK 4661/4885CTSS 4022/4885CTSL 1563/4885 |
| US-20250241926-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | CTSK 1668/4885CTSS 1842/4885CTSL 2531/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | CTSK 1492/4885CTSS 1158/4885CTSL 1007/4885 |
| US-20260008750-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING PRODUCTION OF TRIMETHYLAMINE | SLC6A6, BHMT2, BHMT | CTSK 3175/4885CTSS 3769/4885CTSL 4577/4885 |
| US-20040249187-A1 | Method for producing chiral amino acid derivatives | ADH5, AADAT, NOS2 | CTSK 4469/4885CTSS 4651/4885CTSL 4392/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | CTSK 1467/4885CTSS 1044/4885CTSL 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.